Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration
TerminatedNAResults postedLast updated 13 January 2025
What this trial tests
NA trial testing Low frequency repetitive transcranial magnetic stimulation (rTMS) in Alcohol Use Disorder in 9 participants. Terminated before completion.
Timeline
8 October 2021
Primary endpoint 25 April 2022
2 June 2022
Quick facts
Lead sponsor
Indiana University
Phase
NA
Status
Terminated
Study type
INTERVENTIONAL
Allocation
randomized
Design
crossover
Masking
quadruple
Primary purpose
treatment
Enrollment
9
Start date
8 October 2021
Primary completion
25 April 2022
Estimated completion
2 June 2022
Sites
1 location across United States
Drugs / interventions tested
Low frequency repetitive transcranial magnetic stimulation (rTMS)
Alcohol consumption as measured by Time Line Follow Back (TLFB) comparing drinking baseline (5 weeks prior to study) with post-treatment during the 5-week follow-up period. The Timeline Follow-back (TLFB) is uses a calendar to assess a subject's retrospective estimates of their daily drinking.
Group
Value
95% CI
Low Frequency Repetitive Transcranial Magnetic Stimulation (rTMS)
14.8
± 4.9
Sham rTMS Stimulation
7.8
± 3.5
Sponsor's own description
This will be a single site randomized, 2-session, within-subject cross-over design pilot study. 20 enrolled (of 30 consented) subjects reporting varying levels of binge and high intensity drinking, defined as at least 2 episodes of drinking 4 (for women) or 5 (for men) drinks on an occasion over the last 5 weeks, (unless determined by PI that drinking history meets study objectives), will be enrolled. Subjects will be randomized to undergo one session of repetitive transcranial magnetic stimulation (rTMS) or sham immediately followed by the investigators rate control intravenous (IV) alcohol self-administration (ASA) paradigm. Subjects will then return 7-14 days later and undergo the same sequence of events with the opposite intervention (i.e. rTMS or sham) from session 1.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indiana University
Last refreshed: 13 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04971681.